SYNCHRONY Real-World is a Phase 3 randomized, double-blind, placebo controlled study evaluating the safety and tolerability of EFX in patients with suspected or confirmed clinical diagnosis of ...

Before its conduct, this clinical study was approved by the Institutional Review Board at each study site ... of subjects who advanced to the double-blind phase are shown in Table 1.

T-VEC was administered at ≤ 4 × 10 6 plaque-forming unit (PFU) followed by ≤ 4 × 10 8 PFU 3 weeks later and once ... This randomized, double-blinded, placebo-controlled, multicenter, international ...

A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer. This is an ASCO Meeting Abstract from the 2023 ASCO ...

I congratulate and thank our team at Morton Plant Hospital for achieving this important milestone in enrolling the first patient in the world’s first confirmatory Phase 3 cardiac cell therapy ...